Skip to main content

Estimado (a) Dr. (a),

Al abordar a un paciente que vive con obesidad hay que hacerlo con un enfoque peso-incluyente. Es imprescindible realizar un manejo integral que incluya intervenciones en el estilo de vida, terapia cognitivo conductual, tratamiento farmacológico y, de última instancia, cirugía metabólica.

En esta píldora se profundizará en cada uno de estos temas con la finalidad de lograr un efecto sostenible y así reducir el riesgo de posibles complicaciones a futuro.

Material desarrollado por Dr. Eduardo Fernández Campuzano. Médico Cirujano. Especialista en Medicina Interna. Cédula profesional: 3859036, Cédula especialidad: 5052347.

 

Referencias:

  1. Cao B, et al. Interventions targeting comorbid depression and overweight/obesity: A systematic review. Journal of Affective Disorders 314 (2022) 222–232
  2. Mauldin K, May m, Clifford D. The consequences of a weight‐centric approach to healthcare: A case for a paradigm shift in how clinicians address body weight. Nutr. Clin. Pract. 2022;1–16.
  3. Gossmann M, Butsch WS, Jastreboff AM. Treating the Chronic Disease of Obesity. Med Clin N Am 105 (2021) 983–1016
  4. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight Management. N Engl J Med 2015;373(1):11–22.
  5. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375(4):311–22
  6. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376(9741):595–605.
  7. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (CORII). Obesity (Silver Spring) 2013;21(5):935–43
  8. Lewis KH, Fischer H, Ard J, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity 2019;27(4):591–602.
  9. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 2012;20(2):330–42
  10. Gorgojo-Martínez JJ, et al. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study. Int J of Clin Pract. 2019:73(11). 
  11. Gadde KM, et al. Obesity: Pathophysiology and Management. J Am Coll Cardiol. 2018 January 02; 71(1): 69–84.
  12. Kheniser K, Saxon DR, Kashyap SR. Long-Term Weight Loss Strategies for Obesity. J Clin Endocrinol Metab. 2021 Jul; 106(7): 1854–1866.
  13. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes — 5-year outcomes. N Engl J Med 2017;376(7): 641–51
  14. Raynor HA, Champagne CM. Position of the academy of nutrition and dietetics: interventions for the treatment of overweight and obesity in adults. J Acad Nutr Diet 2016;116(1):129–47

 

Material exclusivo para profesionales de la salud.

La información aquí presentada es opinión del ponente.

Material desarrollado con fines de educación médica continua.

Código interno de aprobación: MX22SX00134.

Leave a Reply